144 related articles for article (PubMed ID: 38844490)
1. PDZ2-conjugated-PLGA nanoparticles are tiny heroes in the battle against SARS-CoV-2.
Giacon N; Lo Cascio E; Pennacchietti V; De Maio F; Santarelli G; Sibilia D; Tiberio F; Sanguinetti M; Lattanzi W; Toto A; Arcovito A
Sci Rep; 2024 Jun; 14(1):13059. PubMed ID: 38844490
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Envelope (E) protein interacts with PDZ-domain-2 of host tight junction protein ZO1.
Shepley-McTaggart A; Sagum CA; Oliva I; Rybakovsky E; DiGuilio K; Liang J; Bedford MT; Cassel J; Sudol M; Mullin JM; Harty RN
PLoS One; 2021; 16(6):e0251955. PubMed ID: 34106957
[TBL] [Abstract][Full Text] [Related]
3. Different electrostatic forces drive the binding kinetics of SARS-CoV, SARS-CoV-2 and MERS-CoV Envelope proteins with the PDZ2 domain of ZO1.
Pennacchietti V; Toto A
Sci Rep; 2023 May; 13(1):7906. PubMed ID: 37193746
[TBL] [Abstract][Full Text] [Related]
4. Monomeric and dimeric states of human ZO1-PDZ2 are functional partners of the SARS-CoV-2 E protein.
Giacon N; Lo Cascio E; Davidson DS; Polêto MD; Lemkul JA; Pennacchietti V; Pagano L; Zamparelli C; Toto A; Arcovito A
Comput Struct Biotechnol J; 2023; 21():3259-3271. PubMed ID: 37293240
[TBL] [Abstract][Full Text] [Related]
5. Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity.
Park SH; Siddiqi H; Castro DV; De Angelis AA; Oom AL; Stoneham CA; Lewinski MK; Clark AE; Croker BA; Carlin AF; Guatelli J; Opella SJ
PLoS Pathog; 2021 May; 17(5):e1009519. PubMed ID: 34003853
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-Domain-2 of Host Tight Junction Protein ZO1.
Shepley-McTaggart A; Sagum CA; Oliva I; Rybakovsky E; DiGuilio K; Liang J; Bedford MT; Cassel J; Sudol M; Mullin JM; Harty RN
bioRxiv; 2020 Dec; ():. PubMed ID: 33398268
[TBL] [Abstract][Full Text] [Related]
7. A short sequence in the tail of SARS-CoV-2 envelope protein controls accessibility of its PDZ-binding motif to the cytoplasm.
Neitthoffer B; Alvarez F; Larrous F; Caillet-Saguy C; Etienne-Manneville S; Boëda B
J Biol Chem; 2024 Jan; 300(1):105575. PubMed ID: 38110034
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the SARS-CoV-2 E Protein: Sequence, Structure, Viroporin, and Inhibitors.
Cao Y; Yang R; Lee I; Zhang W; Sun J; Wang W; Meng X
Protein Sci; 2021 Jun; 30(6):1114-1130. PubMed ID: 33813796
[TBL] [Abstract][Full Text] [Related]
9. Host PDZ-containing proteins targeted by SARS-CoV-2.
Caillet-Saguy C; Durbesson F; Rezelj VV; Gogl G; Tran QD; Twizere JC; Vignuzzi M; Vincentelli R; Wolff N
FEBS J; 2021 Sep; 288(17):5148-5162. PubMed ID: 33864728
[TBL] [Abstract][Full Text] [Related]
10. Domain-swapped dimerization of the second PDZ domain of ZO2 may provide a structural basis for the polymerization of claudins.
Wu J; Yang Y; Zhang J; Ji P; Du W; Jiang P; Xie D; Huang H; Wu M; Zhang G; Wu J; Shi Y
J Biol Chem; 2007 Dec; 282(49):35988-99. PubMed ID: 17897942
[TBL] [Abstract][Full Text] [Related]
11. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of coronavirus E protein interactions with human PALS1 PDZ domain.
Javorsky A; Humbert PO; Kvansakul M
Commun Biol; 2021 Jun; 4(1):724. PubMed ID: 34117354
[TBL] [Abstract][Full Text] [Related]
13. Comparing the binding properties of peptides mimicking the Envelope protein of SARS-CoV and SARS-CoV-2 to the PDZ domain of the tight junction-associated PALS1 protein.
Toto A; Ma S; Malagrinò F; Visconti L; Pagano L; Stromgaard K; Gianni S
Protein Sci; 2020 Oct; 29(10):2038-2042. PubMed ID: 32822073
[TBL] [Abstract][Full Text] [Related]
14. Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.
Saify Nabiabad H; Amini M; Demirdas S
Chem Biol Drug Des; 2022 Feb; 99(2):233-246. PubMed ID: 34714580
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target.
Xia B; Shen X; He Y; Pan X; Liu FL; Wang Y; Yang F; Fang S; Wu Y; Duan Z; Zuo X; Xie Z; Jiang X; Xu L; Chi H; Li S; Meng Q; Zhou H; Zhou Y; Cheng X; Xin X; Jin L; Zhang HL; Yu DD; Li MH; Feng XL; Chen J; Jiang H; Xiao G; Zheng YT; Zhang LK; Shen J; Li J; Gao Z
Cell Res; 2021 Aug; 31(8):847-860. PubMed ID: 34112954
[TBL] [Abstract][Full Text] [Related]
17. Receptor-Loaded Virion Endangers GPCR Signaling: Mechanistic Exploration of SARS-CoV-2 Infections and Pharmacological Implications.
Zhang Q; Friedman PA
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681624
[TBL] [Abstract][Full Text] [Related]
18. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
20. Coronavirus virulence genes with main focus on SARS-CoV envelope gene.
DeDiego ML; Nieto-Torres JL; Jimenez-Guardeño JM; Regla-Nava JA; Castaño-Rodriguez C; Fernandez-Delgado R; Usera F; Enjuanes L
Virus Res; 2014 Dec; 194():124-37. PubMed ID: 25093995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
